MedTrace Logo

Phase II Iressa & Carbo/Gem in NSCLC

NCT00264498 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2009-08-03

Study results available
· View outcomes & findings →

Summary

The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Gefitinib

oral tablet

DRUG

Gemcitabine

intravenous injection

DRUG

Carboplatin

intravenous injection

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Canada Oncology Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Completion
2008-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264498 on ClinicalTrials.gov